DRI Healthcare TrustDHTRF 33 Buyback Yield % is 2.24 as of Jul. 09, 2026, which is 133% above its 10-year median of 0.96. GuruFocus rates DHTRF with a GF Score™ of 33/100 and a GF Value™ of $13.34 (Fairly Valued). The stock has 4 warning signs investors should review. Among 291 Drug Manufacturers companies, DRI Healthcare Trust ranks better than 91.07% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
DRI Healthcare Trust Buyback Yield % Related Terms
DRI Healthcare Trust Buyback Yield % Historical Data
* Premium members only.
The historical data trend for DRI Healthcare Trust's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DRI Healthcare Trust's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DRI Healthcare Trust Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DRI Healthcare Trust's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where DRI Healthcare Trust's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRI Healthcare Trust (DHTRF) has a Buyback Yield % of 2.24 as of Jul. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DRI Healthcare Trust and its competitors. This is 133% above median its historical median of 0.96. According to the industry distribution chart, DRI Healthcare Trust ranks #26 out of 291 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is DRI Healthcare Trust's Buyback Yield % too high?
DRI Healthcare Trust's current Buyback Yield % of 2.24 is 133% above median its 10-year median of 0.96. Based on the distribution chart, DRI Healthcare Trust ranks #26 out of 291 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DRI Healthcare Trust has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DRI Healthcare Trust's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DRI Healthcare Trust ranks #26 out of 291 companies for Buyback Yield %. This places DRI Healthcare Trust in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DRI Healthcare Trust and its competitors. DRI Healthcare Trust's current Buyback Yield % is 2.24, which is 133% above median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DRI Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, DRI Healthcare Trust (DHTRF) is currently considered Fairly Valued. The stock's GF Value™ is $13.34, compared to a current price of $12.70 — trading 4.8% below its estimated fair value. The current Buyback Yield % is 2.24, which is 133% above median its 10-year median of 0.96. DRI Healthcare Trust's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For DRI Healthcare Trust (DHTRF), the current Buyback Yield % is 2.24 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DRI Healthcare Trust (DHTRF) Overvalued in 2026?
Based on GuruFocus' analysis, DRI Healthcare Trust stock appears to be undervalued.
The current stock price of $12.70 is trading 4.8% below its estimated GF Value™ of $13.34.
GuruFocus considers DRI Healthcare Trust to be Fairly Valued.
Key valuation signals for DHTRF:
Buyback Yield %: 2.24 (133% above median its 10-year median of 0.96)
GF Value™: $13.34 vs. price of $12.70 (4.8% below fair value)
No single metric tells the full story. See the DHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DRI Healthcare Trust is an open-ended trust that purchases royalty entitlements on products that address unmet medical needs, providing its unitholders with top-line exposure to a portfolio of therapeutics. Its portfolio comprises several royalty streams on products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically, it generates maximum royalty income from the sale of products underlying its royalty agreements in the United States, followed by other markets such as Japan, the European Union, and the rest of the world.
33GF Score
Get the complete analysis for DHTRF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHTRF has been successfully added to your 
